image
Technology - Software - Application - NASDAQ - US
$ 35.015
-0.987 %
$ 5.55 B
Market Cap
-121.03
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one VERX stock under the worst case scenario is HIDDEN Compared to the current market price of 35 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one VERX stock under the base case scenario is HIDDEN Compared to the current market price of 35 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one VERX stock under the best case scenario is HIDDEN Compared to the current market price of 35 USD, Vertex, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VERX

image
$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
667 M REVENUE
16.49%
-2.23 M OPERATING INCOME
69.99%
-52.7 M NET INCOME
-302.73%
165 M OPERATING CASH FLOW
121.74%
-158 M INVESTING CASH FLOW
-139.00%
231 M FINANCING CASH FLOW
973.26%
177 M REVENUE
-0.78%
4.49 M OPERATING INCOME
134.23%
11.1 M NET INCOME
116.42%
14.8 M OPERATING CASH FLOW
-64.01%
-17.8 M INVESTING CASH FLOW
28.28%
-20.7 M FINANCING CASH FLOW
-330.34%
Balance Sheet Vertex, Inc.
image
Current Assets 536 M
Cash & Short-Term Investments 305 M
Receivables 164 M
Other Current Assets 66.7 M
Non-Current Assets 630 M
Long-Term Investments 0
PP&E 190 M
Other Non-Current Assets 441 M
26.16 %14.09 %5.72 %16.24 %37.79 %Total Assets$1.2b
Current Liabilities 537 M
Accounts Payable 36.2 M
Short-Term Debt 4.07 M
Other Current Liabilities 497 M
Non-Current Liabilities 450 M
Long-Term Debt 348 M
Other Non-Current Liabilities 102 M
3.67 %50.34 %35.22 %10.35 %Total Liabilities$987.4m
EFFICIENCY
Earnings Waterfall Vertex, Inc.
image
Revenue 667 M
Cost Of Revenue 241 M
Gross Profit 426 M
Operating Expenses 428 M
Operating Income -2.23 M
Other Expenses 50.5 M
Net Income -52.7 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)667m(241m)426m(428m)(2m)(51m)(53m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.91% GROSS MARGIN
63.91%
-0.33% OPERATING MARGIN
-0.33%
-7.91% NET MARGIN
-7.91%
-29.40% ROE
-29.40%
-4.52% ROA
-4.52%
9.71% ROIC
9.71%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vertex, Inc.
image
100m100m90m90m80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0020192019202020202021202120222022202320232024202420252025
Net Income -52.7 M
Depreciation & Amortization 86.7 M
Capital Expenditures -65.8 M
Stock-Based Compensation 47.4 M
Change in Working Capital 0
Others 32.3 M
Free Cash Flow 99.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vertex, Inc.
image
Wall Street analysts predict an average 1-year price target for VERX of $50 , with forecasts ranging from a low of $37 to a high of $62 .
VERX Lowest Price Target Wall Street Target
37 USD 5.67%
VERX Average Price Target Wall Street Target
50 USD 42.80%
VERX Highest Price Target Wall Street Target
62 USD 77.07%
Price
Max Price Target
Min Price Target
Average Price Target
65656060555550504545404035353030Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Vertex, Inc.
image
Sold
0-3 MONTHS
45.5 M USD 4
3-6 MONTHS
5.62 M USD 2
6-9 MONTHS
210 M USD 8
9-12 MONTHS
138 M USD 8
Bought
0 USD 0
0-3 MONTHS
299 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vertex (VERX) Moves 5.0% Higher: Will This Strength Last? Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 1 week ago
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine. This next-in-class triple combination treatment is licensed for people living with CF aged 6. businesswire.com - 1 week ago
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology. “We are honored to be recognized at Premier's 2025. businesswire.com - 1 week ago
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term data shows durable, life-changing benefits for SCD and TDT patients, but adoption is limited by a complex, intensive treatment process. Current Casgevy revenues are modest, but improvements to preconditioning and in-vivo approaches could unlock blockbuster potential by 2030. seekingalpha.com - 2 weeks ago
Vertex to Announce Second Quarter 2025 Financial Results on August 4th BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2025 Earnings Call.” The conference call will be webcast live and a link to the webcast can. businesswire.com - 2 weeks ago
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older. zacks.com - 3 weeks ago
Vertex's next-generation cystic fibrosis drug gets EU approval Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis. reuters.com - 3 weeks ago
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further. businesswire.com - 3 weeks ago
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold. zacks.com - 3 weeks ago
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential b. businesswire.com - 1 month ago
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the Americ. businesswire.com - 1 month ago
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year's E. businesswire.com - 1 month ago
8. Profile Summary

Vertex, Inc. VERX

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 5.55 B
Dividend Yield 0.00%
Description Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Contact 2301 Renaissance Boulevard, King of Prussia, PA, 19406 https://www.vertexinc.com
IPO Date July 29, 2020
Employees 1900
Officers Mr. David DeStefano Chief Executive Officer, President & Chairman of the Board Mr. Bryan T. R. Rowland Senior Vice President, General Counsel & Secretary Mr. Salvatore Visca Chief Technology Officer Mr. Ben Askin Chief Information Officer Mr. Ryan J. Leib CPA Chief Accounting Officer Mr. Ray Westphal Founder Ms. Stefanie Westphal-Lucas Thompson Co-Owner & Independent Director Mr. John R. Schwab Chief Financial Officer Mr. Steven Hinckley Chief Operating Officer Ms. Amanda Westphal Radcliffe Co-Owner & Independent Director